

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM470475

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Valeant Holdings Ireland (Ireland)		04/18/2018	Private Unlimited Company: IRELAND
RECEIVING PARTY DATA			
Name:	Valeant Pharmaceuticals Ireland Limited		
Street Address:	3103 Lake Drive		
Internal Address:	Citywest Business Campus		
City:	Dublin		
State/Country:	IRELAND		
Postal Code:	24		
Entity Type:	Limited Company: IRELAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	4231795	ONEXTEN	
CORRESPONDENCE DATA			
Fax Number:	5852322152		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	585-232-6500		
Email:	kmarkert@hselaw.com		
Correspondent Name:	Katherine A. Markert		
Address Line 1:	1600 Bausch & Lomb Place		
Address Line 2:	Harter Secrest & Emery LLP		
Address Line 4:	Rochester, NEW YORK 14604		
NAME OF SUBMITTER:	Katherine A. Markert		
SIGNATURE:	/Katherine A. Markert/		
DATE SIGNED:	04/19/2018		
Total Attachments: 2			
source=Assignment VHI-VIRL_Onexton (Signed)#page1.tif			
source=Assignment VHI-VIRL_Onexton (Signed)#page2.tif			

CH \$40.00 4231795

TRADEMARK ASSIGNMENT

This Trademark Assignment is effective as of April 18, 2018 (the "Effective Date"), by and between Valeant Holdings Ireland (Ireland) a Private Unlimited Company with Share Capital established and existing under the laws of Ireland with a place of business at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignor") and Valeant Pharmaceuticals Ireland Limited a limited company established and existing under the laws of Ireland having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignee").

WHEREAS, Assignor is the owner of U.S. Trademark Registration No. 4231795 for the mark ONEXTEN for "pharmaceutical preparations and substances for the treatment of diseases, illnesses, disorders, ailments or conditions of the central nervous system; pharmaceutical preparations and substances for the treatment of depression, depressive disorders and mental illnesses; antidepressants; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the treatment of anxiety; and pharmaceutical preparations and substances for the prevention, treatment, and alleviation of pain" (the "Assigned Trademark"), and the goodwill associated with the Assigned Trademark; and

WHEREAS, Assignor wishes to assign to Assignee and Assignee wishes to receive all of Assignor's right, title, and interest in and to the Assigned Trademark, and the goodwill associated with the Assigned Trademark; and

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged the parties agree as follows:

1. Assignment of Trademarks. Assignor does hereby sell, assign, and transfer to Assignee all of Assignor's right, title, and interest in and to the Assigned Trademark, the goodwill associated with the Assigned Trademarks and the right to sue and recover for past infringement of the Assigned Trademark, as fully and completely as permitted by law, it being the intention of the parties that Assignee shall acquire all rights in the Assigned Trademark, leaving Assignor with no rights whatsoever.

2. Successors and Assigns. This Agreement and all of its provisions shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

4. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have caused this Trademark Assignment to be signed by its duly authorized representative as follows:

**VALEANT HOLDINGS IRELAND
(IRELAND)**

By: Brenda Finnerty
Name: Brenda Finnerty
Title: Director

**VALEANT PHARMACEUTICALS IRELAND
LIMITED**

By: [Signature]
Name: Michael Kennedy
Title: Director

6569370_3